Immunoregulatory Events in the Skin of Patients With Cutaneous T-Cell Lymphoma
- 1 May 1996
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 132 (5) , 554-561
- https://doi.org/10.1001/archderm.1996.03890290088012
Abstract
Background: Involved skin of patients with cutaneous T-cell lymphoma, mycosis fungoides type, contains an increased number of bone marrow—derived epidermal cells that express class II major histocompatibility complex molecules and an infiltrate of both activated non-malignant and malignant T cells. However, the mechanism by which the T cells achieve and maintain their activated state is uncertain. The aim of this article is, therefore, to review recent studies from the literature dealing with immunoregulatory events in patients with mycosis fungoides and Sézary syndrome. Observations: The nonmalignant T cells seem to be activated through the T-cell receptor by lesional epidermal CD1a+CD36+ macrophagelike cells that, on a cell per cell basis, are more potent antigen-presenting cells than normal CD1a+ Langerhans' cells present in uninvolved epidermis. In contrast, the malignant T cells have different activation requirements, because they can only be stimulated through antigen independent pathways, such as CDw60, CD28, and CD2. The malignant T cells produce T-helper (Th)-2 cytokines, and because interferon gamma (IFN-γ)-producing Thl cells are present in the early lesions of mycosis fungoides, nonmalignant tumor-infiltrating T cells may represent Thl cells. Because Thl cytokines counteract Th2 cytokines, tumor-infiltrating T cells may potentially have the capacity to downregulate the growth of the malignant cells. Conclusion: The balance between progression vs remission in mycosis fungoides is related to complex interactions between the malignant T cells, nonmalignant T cells, and hyperstimulative antigen-presenting cells present within the skin. (Arch Dermatol. 1996;132:554-561)This publication has 45 references indexed in Scilit:
- Differences in IL-2 Receptor Levels Between Mycosis Fungoides and Cutaneous Type Adult T-Cell Leukemia/Lymphoma in the Early Stages of the DiseaseJournal of Investigative Dermatology, 1994
- A subpopulation of Langerhans cells (CD1a+Lag- ) increased in the dermis of plaque lesions of mycosis fungoidesJournal of the American Academy of Dermatology, 1991
- Cutaneous T-Cell Lymphoma Lesional Epidermal Cells Activate Autologous CD4+ T Lymphocytes: Involvement of Both CD1+OKM5+ and CD1+OKM5− Antigen-Presenting CellsJournal of Investigative Dermatology, 1990
- Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiologyJAMA, 1988
- Expression of OKM5 Antigen on Epidermal Cells in Mycosis Fungoides Plaque StageJournal of Investigative Dermatology, 1988
- Occurrence of human T cell lymphotropic virus (type I) antibodies in cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1986
- The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant LymphocytesScience, 1986
- Second malignancies in cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1984
- A monoclonal antibody technique to demonstrate an increase in Langerhans cells in cutaneous lesions of mycosis fungoidesClinical and Experimental Dermatology, 1982
- Mycosis fungoides—a disease of antigen persistenceBritish Journal of Dermatology, 1974